Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
ONCOLOGY CLINICAL TRIALS OPEN AT THE BON SECOURS HOSPITAL, CORK BREAST CANCER TRIALS CADY: Detection of Cardiac Dysfunction in Patients Treated with Trastuzumab for HER2 Positive Breast Cancer. RESLIENCE TRIAL: A Phase III Randomized, double-blind, placebo-controlled trial comparing Capecitabine plus Sorafenib versus Capecitabine plus placebo in the treatment of locally advanced or metastatic HER2-negative breast cancer. MYOCET & LAPATINIB TRIAL: Phase I/II study of lapatinib plus Myocet TM patients with HER2+ve metastatic breast cancer following disease progression during, or after, treatment with trastuzumab and taxanes. SOLE TRIAL: Study of Letrozole Extension(SOLE study) A phase III trial evaluating the role of continuous letrozole versus intermittent letrozole following 4 to 6 years of prior adjuvant endocrine therapy for postmenopausal women with hormone-receptor positive, node positive early stage breast cancer. TCHL TRIAL: A phase II neo-adjuvant study assessing TCH (Docetaxel, Carboplatin and Trastuzumab), TCL (Docetaxel, Carboplatin and Lapatinib) and the combination of TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in ErbB2+ve breast cancer patients. EOS TRIAL (European Observation & Survey ) : A 6 month follow up of women treated for metastatic breast cancer in Europe. COLORECTAL CANCER TRIALS SNP TRIAL: Correlation of Single Nucleotide Polymorphism (SNP) profile of domain III of EGFR to skin toxicity and disease response to treatment with Cetuximab. GASTROINTESTINAL CANCER TRIALS SORAFENIB TRIAL: Phase II study of single agent sorafenib in the treatment of relapsed oesophageal/gastric adenocarcinoma in platinum pre-treated patients. HAEMATOLOGY TRIALS LYMPHOMA TRIAL: An open label, randomized phase III trial of Inotuzumab Ozogamicin administered in combination with Rituximab compared to defined investigator's choice therapy in subjects with relapsed or refractory CD22 positive NonHodgkin Lymphoma who are not candidates for intensive high dose chemotherapy.